You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

ANZEMET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Anzemet, and what generic alternatives are available?

Anzemet is a drug marketed by Validus Pharms and is included in two NDAs.

The generic ingredient in ANZEMET is dolasetron mesylate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolasetron mesylate profile page.

Drug patent expirations by year for ANZEMET
Drug Prices for ANZEMET

See drug prices for ANZEMET

Recent Clinical Trials for ANZEMET

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of PittsburghPhase 2
David A. Clump, MD, PhDPhase 2
University of Southern CaliforniaN/A

See all ANZEMET clinical trials

Pharmacology for ANZEMET

US Patents and Regulatory Information for ANZEMET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-001 Sep 11, 1997 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-003 Dec 11, 2001 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ANZEMET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-001 Sep 11, 1997 ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-003 Dec 11, 2001 ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 ⤷  Try a Trial ⤷  Try a Trial
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ANZEMET

See the table below for patents covering ANZEMET around the world.

Country Patent Number Title Estimated Expiration
Finland 891954 ⤷  Try a Trial
Japan S63146855 ESTER OF 3-TERTIARY-BUTYL OR 3-TERTIARY-BUTYL- 5-ALKYL-4-HYDROXYPHENYL-(ALKANE)-CARBOXYLIC ACID AND OXYETHYLATE OF POLYTHIOLS, ITS PRODUCTION AND ITS USE AS STABILIZER ⤷  Try a Trial
European Patent Office 0329902 ⤷  Try a Trial
Ireland 63670 Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds ⤷  Try a Trial
Canada 1329203 ESTERS DE L'HEXAHYDRO-8HYDROXY-2, 6-METHANO-2H-QUINOLIZIN-3 (4H)-ONE ET COMPOSES CONNEXES (ESTERS OF HEXAHYDRO-8-HYDROXY-2, 6-METHANO-2H- QUINOLIZIN-3(4H)-ONE AND RELATED COMPOUNDS) ⤷  Try a Trial
Canada 1325634 ESTERS D'HEXAHYDRO-8-HYDROXY-2,6-METHANO-2H-QUINOLIZIN-3 (4H)-ONE, ET COMPOSES ANNEXES (ESTERS OF HEXAHYDRO-8-HYDROXY-2,6-METHANO-2H- QUINOLIZIN-3(4H)-ONE AND RELATED COMPOUNDS) ⤷  Try a Trial
Denmark 175643 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ANZEMET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0266730 98C0014 Belgium ⤷  Try a Trial PRODUCT NAME: MIGLITOL; NAT. REGISTRATION NO/DATE: NL 22 138 19970204; FIRST REGISTRATION: NL - 19 343 UR 19960723
0266730 SPC/GB97/005 United Kingdom ⤷  Try a Trial PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926
0266730 73/1997 Austria ⤷  Try a Trial PRODUCT NAME: ANZEMET; NAT. REGISTRATION NO/DATE: 1-22014, 1-22015, 1-22016 19970624; FIRST REGISTRATION: GB PL 04425/0150 19960926
0266730 C970043 Netherlands ⤷  Try a Trial PRODUCT NAME: DOLASETRON, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; NAT REGISTRATION NO/DATE: RVG 21707 - RVG 21709 19970623; FIRST REGISTRATION: GB PL 04425/0150, PL 04425/0152, PL 04425/0154 19960926
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.